These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26123382)

  • 1. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
    Capozzi M; Caterina I; De Divitiis C; von Arx C; Maiolino P; Tatangelo F; Cavalcanti E; Di Girolamo E; Iaffaioli RV; Scala S; Tafuto S;
    Int J Surg; 2015 Sep; 21 Suppl 1():S89-94. PubMed ID: 26123382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors.
    Antonuzzo L; Del Re M; Barucca V; Spada F; Meoni G; Restante G; Danesi R; Di Costanzo F; Fazio N
    Cancer Treat Rev; 2017 Jun; 57():28-35. PubMed ID: 28535439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus.
    Hasskarl J
    Recent Results Cancer Res; 2018; 211():101-123. PubMed ID: 30069763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.
    Gallo M; Malandrino P; Fanciulli G; Rota F; Faggiano A; Colao A;
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1209-1224. PubMed ID: 28405826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
    Rose DB; Nellesen D; Neary MP; Cai B
    J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
    Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
    Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
    Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
    Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
    Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the mTOR signaling pathway in neuroendocrine tumors.
    Chan J; Kulke M
    Curr Treat Options Oncol; 2014 Sep; 15(3):365-79. PubMed ID: 25092520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
    Cho CM
    Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic neuroendocrine tumors: entering a new era.
    Oberstein PE; Remotti H; Saif MW; Libutti SK
    JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
    Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
    Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
    Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
    Maxwell JE; Sherman SK; Howe JR
    Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.
    Lee KJ; Cho JH; Lee SH; Song SY; Lee KH; Jeong S; Ryu JK; Woo SM; Bang S; Lee JK; Lee TH; Paik WH; Kim YT; Lee WJ
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):799-805. PubMed ID: 28884280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.